§ VNAsia-Pacific
🇻🇳

Vietnam

Drug Administration of Vietnam (DAV)

GEBy GlobalReg EditorialLast verified 4/25/2026
Updated 6 days agomedium confidence
Export PDF
Lead approval timeline
240–365 days
180–365 days · Reliance / Reference Visa (SRA-approved products)
Application fee
VND 11M
VND 11,000,000 · Per fee schedule
English submissions
Accepted
Vietnamese, English
eCTD
CTD only
See dossier notes
Local representative
Required
RP also required
Reliance pathway
Available
8 reference agencies
Last verified 4/25/2026 · by GlobalReg Editorial
What this means: A snapshot of who regulates medicines in this country, what languages they accept, and which international standards they recognise.
Country brief
Vietnam

Vietnam regulates pharmaceutical products through the Drug Administration of Vietnam (DAV, Cục Quản lý Dược), an agency of the Ministry of Health (MoH). The legal framework is the Pharmacy Law 2016 (No. 105/2016/QH13, as amended in 2024 by Law No. 44/2024/QH15) and subordinate Decrees and Circulars. Marketing authorisation is evidenced by a Visa (Số đăng ký lưu hành thuốc), valid for 3 or 5 years depending on product class. DAV's procedures were modernised by Circular 08/2022/TT-BYT (which simplified administrative procedures and allowed renewals via auto-extension), and most recently updated by Circular 12/2025/TT-BYT (issued 16 May 2025) which further refines registration and lifecycle requirements. Vietnam is an ASEAN member and applies ACTD/ACTR; it operates Standard, Generic, Vaccine/Biological and Reliance / SRA-recognition pathways. Public-sector reimbursement is anchored on the Vietnam Social Security (VSS) scheme administered by the Vietnam Social Security agency, with the Ministry of Health Drug List (Reimbursement List, Thông tư 20/2022/TT-BYT and successors) as the gatekeeper for VSS coverage. Centralised procurement at MoH and provincial Department of Health levels drives hospital-channel access.

Verified 4/25/2026 · GlobalReg Editorial
Regulatory authority
DAV
Operating language
Vietnamese (English accepted for technical CTD sections)
English submissions
Accepted
Submission languages
Vietnamese, English
CTD format
Accepted
eCTD format
Not accepted

About the authority

DAV is the national regulatory authority for medicines in Vietnam, operating as a department of the Ministry of Health. It administers product registration (visa issuance), GMP / GPP / GDP / GLP licensing, controlled substances, pharmacovigilance and post-market surveillance. Statutory registration decisions are taken by the Director of DAV on the recommendation of the DAV Drug Advisory Council. Vietnam's National Centre of Drug Information and Adverse Drug Reactions Monitoring (DI&ADR Centre) administers pharmacovigilance.

International affiliations

WHOPIC/S applicantICH ObserverASEAN PPWG
Visit official website

Reliance & recognition

DAV recognises Stringent Regulatory Authority (SRA) approvals and WHO Prequalification under the reliance / reference-visa procedures introduced by Circular 08/2022/TT-BYT and refined by Circular 12/2025/TT-BYT. ASEAN harmonisation (ACTD/ACTR) supports cross-recognition within ASEAN.

FDA (US)EMAMHRA (UK)Health CanadaTGA (Australia)PMDA (Japan)SwissmedicWHO Prequalification

Compare Vietnam side-by-side

Benchmark timelines, fees and pathway requirements against another market.

Other Asia-Pacific markets

Same structure. Same source-citation standard.